Clarient Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry has entered into an agreement with pharmaceutical leader Eli Lilly and Company.
According to a company release, Clarient's biopharma business unit will provide various biopharmaceutical research services.
"We look forward to supporting Lilly with our scientific expertise utilising advanced technology platforms to provide a solution for the development of companion diagnostics for emerging therapies," said Clarient's medical director, Kenneth J. Bloom.
Clarient's president and CEO Ron Andrews said, "The Company's strategy in the biopharmaceutical sector involves providing fee-based services and technologies to those companies engaged in the drug discovery process. The revenue provided by those relationships is complemented by additional opportunities for growth in the future as companion diagnostics are developed, based on Clarient technologies, for new cancer drugs."
Clarient provides market leading technologies, services and expert support for the characterisation, assessment and treatment of cancer, leading to more accurate diagnoses by pathologists, more confident treatment decisions by oncologists, a more efficient way to identify and develop pharmaceuticals and, ultimately, better outcomes for patients.